CD274 and non-small cell lung carcinoma: PD‐L1 expression level could be a biomarker for response to anti‐PD‐1 treatment [17, 18], and the mutational landscapes have also been characterized to predict the sensitivity to anti‐PD‐1 treatment in NSCLC.